Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial.

作者: Astrid Van Tubergen , Annelies Boonen , Robert Landewé , Maureen Rutten-Van Mölken , Désirée Van Der Heijde

DOI: 10.1002/ART.10658

关键词:

摘要: Objective To evaluate the cost effectiveness and utility of a 3-week course combined spa therapy exercise in addition to standard treatment consisting antiinflammatory drugs weekly group physical ankylosing spondylitis (AS) patients. Methods A total 120 Dutch outpatients with AS were randomly allocated into 3 groups 40 patients each. Group 1 was treated resort Bad Hofgastein, Austria; 2 Arcen, The Netherlands. control stayed at home continued their usual activities during intervention weeks. After intervention, all followed therapy. study period Effectiveness assessed by functional ability using Bath Ankylosing Spondylitis Function Index (BASFI). Utilities measured EuroQoL (EQ-5Dutility). A time-integrated summary score defined clinical effects (BASFI-area under curve [AUC]) utilities (EQ-5Dutility-AUC) over time. Both direct (health care non-health care) indirect costs included. Resource utilization absence from work registered diary. All calculated societal perspective. Results A 111 completed between-group difference for BASFI-AUC 1.0 (95% confidence interval [95% CI] 0.4–1.6; P = 0.001) versus controls, 0.6 CI 0.1–1.1; 0.020) controls. EQ-5Dutility-AUC 0.17 0.09–0.25; < 0.08 0.00–0.15; 0.04) mean per patient (including therapy) Euros (€) €3,023 1, €3,240 2, €1,754 group. incremental cost-effectiveness ratio unit effect gained (0–10 scale) €1,269 497–3,316) €2,477 601–12,098) 2. quality-adjusted life year €7,465 3,294–14,686) €18,575 3,678–114,257) 2. Conclusion Combined spa–exercise besides is more effective shows favorable cost-utility ratios compared alone AS.

参考文章(27)
P. Allard, J. Deligne, V. Van Bockstael, B. Duquesnoy, Is spa therapy cost-effective in rheumatic disorders? Revue du Rhumatisme. ,vol. 65, pp. 173- 180 ,(1998)
C. Bakker, S. Van Der Linden, E. Van Doorslaer, A. Hidding, Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. The Journal of Rheumatology. ,vol. 21, pp. 264- 268 ,(1994)
H Whitelock, P Mallorie, A Calin, S Garrett, L G Kennedy, J O'Hea, T Jenkinson, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. ,vol. 21, pp. 2281- 2285 ,(1994)
A. Cranney, G. Wells, A. C. Verhoeven, M. Boers, Ba Pham, P. Tugwell, Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. The Journal of Rheumatology. ,vol. 26, pp. 712- 716 ,(1999)
Mariëlle E.J.B Goossens, Maureen P.M.H.Rutten-van Mölken, Johan W.S Vlaeyen, Sjef M.J.P van der Linden, The cost diary: a method to measure direct and indirect costs in cost-effectiveness research Journal of Clinical Epidemiology. ,vol. 53, pp. 688- 695 ,(2000) , 10.1016/S0895-4356(99)00177-8
Simon G Thompson, Julie A Barber, How should cost data in pragmatic randomised trials be analysed? BMJ. ,vol. 320, pp. 1197- 1200 ,(2000) , 10.1136/BMJ.320.7243.1197
A. M. van Tubergen, Robert B. M. Landewé, Sjef van der Linden, Spondylarthropathies: options for combination therapy. Springer Seminars in Immunopathology. ,vol. 23, pp. 147- 163 ,(2001) , 10.1007/S002810100064
Michael Drummond, George Torrance, James Mason, Cost-effectiveness league tables: More harm than good? Social Science & Medicine. ,vol. 37, pp. 33- 40 ,(1993) , 10.1016/0277-9536(93)90315-U
Jan Brandt, Hildrun Haibel, Daniel Cornely, Werner Golder, José Gonzalez, Jaqueline Reddig, Wolfgang Thriene, Joachim Sieper, Jürgen Braun, Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab Arthritis & Rheumatism. ,vol. 43, pp. 1346- 1352 ,(2000) , 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E
Marc A. Koopmanschap, Frans F.H. Rutten, A practical guide for calculating indirect costs of disease. PharmacoEconomics. ,vol. 10, pp. 460- 466 ,(1996) , 10.2165/00019053-199610050-00003